-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $32

Benzinga·11/21/2025 13:44:59
Listen to the news
Jefferies analyst Andrew Tsai initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $32.